CD47 and neoplasm: Systemic tumor growth was measured by bioluminescence revealing a significant anti-tumor activity induced by anti-CD47 mAbs when compared to isotype control (Figures 4A–C) correlating with a prolonged survival of STI-6643 (73%) and Hu5F9 (60%) treated mice as compared to isotype (0%) treated mice (Figure 4D).